Sinthia Bosnic-Anticevich is Professor at the Woolcock Institute of Medical Research, University of Sydney. Internationally recognised as a leader in in the field of respiratory medicines, she is the founder and Team Leader of the Quality Use of Respiratory Medicines Group, located at the Woolcock Institute, University of Sydney and Sydney Local Health District. The group focuses on generating new knowledge about the use of respiratory medicines from the patient, health care provider and societal perspective with output of over 120 research publications. The research of Sinthia and her group has changed the landscape of inhaler technique research; impacting on national and international treatment guidelines. Sinthia is on the executive of ARIA (Allergic Rhinitis in Asthma) and chair of Pharmacy ARIA, which is the leading global initiative for the management of Allergic Rhinitis in pharmacy. She is Vice President of the Respiratory Effectiveness Group (REG). Sinthia sits on several global advisory boards associated with the use of medicines in the management of respiratory diseases. Sinthia is actively involved in the practice of pharmacy and committed to the education of current and future health care providers around the use of respiratory medicines in practice.

Giorgio Walter Canonica is Professor of Respiratory Medicine at Humanitas University & Director Personalized Medicine Asthma & Allergy Center at Humanitas Research Hospital - Milano, Italy. Professor Canonica first specialised in pulmonary diseases after receiving his medical degree from the University of Genoa, Italy. He then specialised in allergy and clinical immunology at Florence University, Italy. He subsequently conducted clinical immunology and allergology research at several European Universities and Institutes, in addition to two years at the Medical University of South Carolina, USA. Since returning to the University of Genoa in 1995, Professor Canonica has held a number of academic positions, including Director of the Speciality School of Allergy and Clinical Immunology, Director of the Specialty School of Pulmonary Diseases and Chairman of the Department of Medical Specialties (University Hospital San Martino Genoa, Italy). He is a Board Member of ARIA-Allergic Rhinitis and its Impact on Asthma and helped to develop their guidelines.
He has been President of WAO-World Allergy Organization, Interasma-Global Asthma Association, currently VicePresident of REG-Respiratory Effectiveness Group.
He is Steering Committee Member of SANI-Severe Asthma Network Italy.

Professor Halpin is Consultant Physician & Honorary Professor in Respiratory Medicine at the University of Exeter. He was appointed as a Consultant in 1994. He has a busy clinical practice and for 13 years he was Clinical Lead for the Department in Exeter, overseeing the growth in its clinical and research activity.
He is also Honorary Professor of Respiratory Medicine at the Observational and Pragmatic Research Institute (OPRI) in Singapore. He is a member of the Board of Directors of the Global Initiative on Obstructive Lung Diseases (GOLD) and of the GOLD Science Committee. He was the Chairman and Clinical Expert for the COPD Guideline Development Group of the National Institute of Clinical Excellence (NICE) in the UK.
He studied at Oxford University (first class honours) & St Thomas Hospital Medical School, qualifying in 1986. He was awarded an MRC scholarship to undertake a D.Phil. in the Department of Human Anatomy at Oxford University, between his pre-clinical and clinical training. He trained in respiratory medicine at the Brompton Hospital in London.
He is a Fellow of Royal College Physicians, and a Member of the BTS, ERS & ATS.
He has served on various BTS committees.
In 2018 he was elected as a Fellow of ERS in recognition of lifetime excellence and contributions to research, education and clinical leadership in respiratory medicine.
His research is focussed on clinical aspects of COPD and asthma. He has published extensively and frequently gives presentations on COPD and asthma at lectures and meetings around the world.
He was an Associate Editor of Thorax and is on the editorial board of several journals and is a peer reviewer for many others.

Janwillem Kocks is a practicing General Practitioner, Professor of Inhalation Medicine at the Observational and Pragmatic Research Institute in Singapore and managing director of the General Practitioners Research Institute.
He obtained his medical degree in 2004 at the University of Groningen. In January 2005 he started his PhD research within the Groningen Research Institute on Asthma and COPD (GRIAC) resulting in his thesis “Towards health status guided care in COPD”. He combined his PhD training with the specialist training for general practitioner and graduated as general practitioner in March 2009 and obtained his PhD in June 2011.
He visited the Medical Research Institute of New Zealand (headed by Professor Richard Beasley) between July 2013 and February 2014 as senior research fellow and was visiting professor at the Observational & Pragmatic Research Institute (headed by Professor David Price) end of 2017.
He is president of the International Primary Care Respiratory Group (IPCRG).
His current research focuses on diagnosis and individualised management of both asthma and COPD in primary care including improving inhalation technique by education and smart inhalers.

Dr Konstantinos Kostikas is Associate Professor of Respiratory Medicine and Head of the Respiratory Medicine Department of the University of Ioannina, Greece, and Professor of Respiratory Medicine at the Observational and Pragmatic Research Institute, Singapore. He was trained at the University of Athens Medical School and the Royal Brompton Hospital, London, and has worked in academia and the pharmaceutical industry in global medical affairs roles.
Dr Kostikas is a member of GOLD COPD Assembly. He has more than 230 publications in PubMed (h-index 38), focusing on COPD, severe asthma, and new technologies. He is the Editor in Chief of Pneumon Journal (www.pneumon.org), associate editor of COPD: Journal of Chronic Obstructive Pulmonary Disease, and member of the editorial board of American Journal of Respiratory and Critical Care Medicine, PLoS One, Diagnostics and Frontiers in Medicine.

Head Of Department Respiratory Medicine, UZA

Director of the Lung Division, Royal Brompton Hospital, London, UK
Professor of Practice (Respiratory Medicine)
National Heart and Lung Institute
Imperial College

Marc Miravitlles is a Pulmonologist at the Hospital Universitari Vall d’Hebron in Barcelona, Spain. He obtained his MD at the Universitat de Barcelona, Barcelona, Spain and then specialised in Respiratory Medicine at Hospital Vall d'Hebron. His primary research interests include chronic obstructive pulmonary disease (COPD), alpha-1-antitrypsin deficiency (AAT), lung defence mechanisms and respiratory infections. He serves on various medical committees and is a member of numerous professional societies, including the Spanish Society of Pneumology and Thoracic Surgery (SEPAR), where he served as Secretary from 1999 until 2003 and responsible for International Relationships from 2006 until 2012. Dr Miravitlles was Chair of the Respiratory Infections Group of the European Respiratory Society (ERS) from 2008 to 2011 and was the Guidelines Director of the ERS from 2015 to 2018. He has acted as a consultant for the development of different international guidelines of COPD, including the American Thoracic Society (ATS)/ERS task force on outcomes in COPD, the ERS/ATS guidelines on exacerbations of COPD and the ERS statement on management of alpha-1 antitrypsin deficiency. He is also a consultant of the Spanish Ministry of Health for the development of the National Strategy Against COPD (2009 to present). He is the coordinator of the Spanish National Guidelines for COPD (GesEPOC from 2012).

Interstitial Lung Disease Unit, Respiratory Medicine Department
Wythenshawe Hospital
Manchester University NHS Foundation Trust
United Kingdom

Dr Rivera Ortega is a Respiratory Consultant with expertise in interstitial lung diseases (ILD), who has been working in the ILD unit of Wythenshawe Hospital since April 2018, for Manchester University NHS Foundation Trust. She is the lead of the Familial Interstitial Pneumonia clinic and the lead of ILD bronchoscopy list at Wythenshawe Hospital. Dr Rivera Ortega has spent three years as a clinical/research fellow and trained as a specialist in ILD with Dr Maria Molina-Molina at Bellvitge University Hospital, Barcelona-Spain. She is the former coordinator of the Emerging Spanish ILD group (GEEPID-SEPAR) and current member of the executive board of the Spanish ILD group (EPID-SEPAR). Dr Rivera Ortega participates as principal investigator and co-investigator of several clinical trials related to ILD. She has previous experience in the development of a rapid circuit for assessment of ILDs.

Prof. Papadopoulos is Professor of Allergy and Paediatric Allergy at the University of Manchester, UK, and the Chair of Allergy and Pediatric Allergy at the University of Athens (NKUA), Greece.
He has extensive clinical and educational experience in paediatric allergy, having headed for many years a unit caring for more than 7,000 children with allergic diseases yearly, implementing state-of-the-art interventions and training medical students, resident paediatricians and allergists. His research focus is the interface between infection and allergic disease, with an emphasis on asthma exacerbations and food allergy. He is the Coordinator of the EU-funded CURE project. He has extensive collaborations in the context of EU projects, such as PreDicta, GA2LEN, EUROPREVALL, iFAAM and FAST. Prof. Papadopoulos has published over 300 papers (h-index: 70), has received several international awards and is invited to speak at international scientific meetings some 30 times a year. Moreover, he has served or is serving on the boards of EAACI, GA2LEN, WAO, EFA and ARIA. He was the 2013–2015 President of EAACI and is currently the President of the Respiratory Effectiveness Group (REG).

Alberto Papi is Professor of Respiratory Medicine at the University of Ferrara, Italy, and Director of the Respiratory Unit of the Department of Emergency Medicine, S. Anna University Hospital, Ferrara, Italy.
He trained in Respiratory Medicine at the University of Parma, before spending 4 years in the UK as a Clinical Research Fellow at the University of Southampton, where he is an Honorary Clinical Lecturer.
He has coordinated several pivotal studies in asthma and COPD, and has authored more than 350 articles in peer-reviewed journals.

James Paton is a Reader in Paediatric Respiratory Disease at the University of Glasgow and is one of 6 specialist paediatric respiratory consultants at the Royal Hospital for Children in Glasgow. Currently, he leads the regional difficult asthma service in Glasgow.
He has a long-standing interest in asthma audit and started the UK paediatric asthma audit. He was the paediatric member of the writing committee National Review of Asthma Deaths Report “Why Asthma Still Kills”. He was co-chair for the last BTS SIGN asthma guideline in 2019.

Paulo Pitrez completed his undergraduate degree in Medicine at the Federal University of Rio Grande do Sul (UFRGS, Porto Alegre, Brazil) in 1993 and undertook his training in Pediatric Pulmonology in 1996 at Hospital de Clínicas de Porto Alegre (Brazil). Prof. Pitrez holds a PhD in Respiratory Medicine (2001), and undertook a clinical and research fellowship at Princess Margaret Hospital for Children/University of Western Australia (Perth, Australia), in 2000. He was the Director of the Institute of Biomedical Research (2008-2017) at Pontifical Catholic University of Rio Grande do Sul (PUCRS, Porto Alegre/Brazil) and Professor of Medicine at PUCRS (2003-2018). He is currently a member of the Science Committee of the Global Initiative for Asthma (GINA), American Thoracic Society, European Respiratory Society, Brazilian Pediatric Society, Brazilian Respiratory Society, World Asthma Organization (Pediatric Committee), and one of the founders and current President of the Brazilian Severe Asthma Group (BraSA Group), a non-governmental organization for patient advocacy. His research interest is focused on pediatric severe asthma, mechanisms of the development of childhood asthma, novel therapies for asthma, the impact of asthma in developing countries, and viral respiratory infections in children. He is currently affiliated to Hospital Moinhos de Vento and leads the Pediatric Severe Asthma Group at Hospital Santa Casa de Porto Alegre.

Respiratory Research Unit, Bispebjerg Hospital

Professor David Price is head of The Observational & Pragmatic Research Institute (Singapore) and Optimum Patient Care (Australia and UK), and is Primary Care Respiratory Society Professor of Primary Care Respiratory Medicine at the University of Aberdeen (UK). His area of interest lies in real life respiratory and allergy research. To date he has authored over 490 peer-reviewed publications and is responsible for approximately US$50 million in research and clinical development grants. In addition he established the Optimum Patient Care Research Database (OPCRD; http://opcrd.co.uk/) with over 8 million patients, and the first International Severe Asthma Registry (ISAR; http://isaregistries.org/) with over 30 countries collaborating. He is currently Editor-in-Chief of Pragmatic and Observational Research and member of the editorial board of several respiratory journals, including The Lancet Respiratory Medicine.

Dr Reddel is a Research Leader at the Woolcock Institute of Medical Research at the University of Sydney; Clinical Adviser for the Australian Centre for Airways disease Monitoring, and a respiratory physician at the Royal Prince Alfred Hospital in Sydney.
As Chair of the Global Initiative for Asthma (GINA) Science Committee, Dr Reddel has led major evidence-based changes in clinical recommendations for asthma management, with a strong focus on improving patient-health professional communication, and on making guidelines not only evidence-based, but also patient-centred and practical.
Dr Reddel has a long history of collaborative research with pharmacists and family physicians to address practical barriers to care of patients with asthma and COPD. Her current research includes investigating clinical trajectories and underlying mechanisms in a real-world cohort of patients with asthma and/or COPD; strategies for identifying and reducing risk in mild asthma; population monitoring of asthma and COPD; and qualitative research about patient perspectives in mild and severe asthma.

Nicolas Roche is Professor of Respiratory Medicine at Cochin Hospital, University of Paris Descartes, France. His major areas of interest are COPD and asthma with particular focus on inhaled therapy, disease phenotypes, assessment tools, treatment strategies and real-life research.
Professor Roche is a member of the GOLD science committee, President of Société de Pneumologie de Langue Française, co-chair of the 2018 ERS Congress and member of the American Thoracic Society. He is guidelines director of the ERS and member of the ERS Clinical Research Collaboration (CRC) working group and ERS Science Council, vice-president of the Respiratory Effectiveness Group and member of the Asthma Drug Management Improvement Team. He coordinates French guidelines on COPD and is a consultant for French institutions for the development of national projects on COPD.
Professor Roche has authored more than 250 research articles in international peer-reviewed journals and edited or co-edited several books on COPD. He is Associate Editor of the European Respiratory Review and the Clinical Respiratory Journal.

Dermot was a GP for over 30 years in the UK. He has championed respiratory and allergy care in the primary care environment over that time. He established the chair of Primary Care Respiratory Medicine at the University of Aberdeen to research "primary care solutions for primary care problems", He is active in research and is a collaborator at the Asthma UK Centre for Applied Research and is also very active in EAACI.

Joan B Soriano graduated in medicine in 1993 and received his PhD in epidemiology and methodology of biomedical research in 1996, both from the Universitat Autònoma de Barcelona. He completed his education in epidemiology with a Master of Science at the Erasmus University, Rotterdam, The Netherlands, and a post-doctoral stay at the Johns Hopkins School of Public Health, in Baltimore, USA. He worked in the pharmaceutical industry in the UK from 1998, and later in the USA from 2003. Then, in 2005 he moved back to CIMERA in Mallorca, Spain. He serves in the GesEPOC COPD guidelines, directed the SEPAR’s Foreign Affairs, participates in several committees of the Ministry of Health of Spain, and collaborates extensively with both the ERS and CHEST. He spends most of his time dedicated to research on COPD and other respiratory conditions, aging and tobacco, the design of new clinical trials and translational medicine. Since 2007 he is an Associate Editor of the European Respiratory Journal and since 2012 of the Lancet Respiratory Medicine. He has published over 270 papers and over 20 book chapters. In May 2011, he received the Josep Trueta Award for scientific and medical achievements, and in 2014 was appointed FCCP of Chest and Foundational Fellow of the ERS.

Omar Usmani is a Reader and Consultant Physician in Respiratory Medicine at the National Heart and Lung Institute (NHLI), Imperial College London and Royal Brompton Hospital. He qualified in Medicine at King’s College London and completed his PhD at Imperial College London for which he received the 2005 NHLI Imperial College PhD Prize for the best thesis.
His clinical research themes are Inhaled Drug Delivery, Airways Physiology, Lung Imaging, Respiratory Pharmacology and Tele-monitoring / E-health. He is Secretary of Assembly 5 (Asthma and COPD) at the ERS, Chair of UKIG (UK Inhaler Group), Vice-Chair of Drug Delivery to the Lungs, and Europe Liaison of International Society of Aerosols in Research (ISAM).
In 2012, he was awarded a UK National Institute for Health Research (NIHR) Career Development Fellowship, the first time this award category was given to Respiratory Science research in the UK. In 2015, received one of the highest accolades in aerosol science, the Thomas T Mercer Award from the American Association of Aerosol Research (AAAR) and ISAM, recognizing his international research excellence in pharmaceutical aerosols and inhalable materials. He is currently clinical lead on an EU Horizon 2020 consortium project ‘myaircoach’ focusing on the tele-monitoring of patients with asthma and is PI of an FDA awarded project on understanding patient perceptions in breathing from a DPI.

Samantha is passionate about the importance of focusing on the needs of real people in the charity’s research and innovation activities in a way that avoids tokenism and enables an equitable share of voice and parity of esteem. Patient organisations can play an important role in helping inform, improve, and help deliver research and by doing so improve outcomes and reduce research waste. Based on our strong track record in involving patients as respected and valued partners in £multi-million UKRI-funded research programmes (eg PHOSP-COVID and RASP-UK), we have set up a successful ‘respiratory insights’ consultancy service for researchers and innovators where we ensure that patients’ needs drive the research question or innovation product being studied, the selection of outcomes and the way the findings are disseminated to the general public and policy makers.

Alexander Moeller is the head of the Division of Respiratory Medicine, the Pediatric Cystic Fibrosis Center and the Center for Sleep Medicine at the University Children’s Hospital Zurich, Switzerland. He is co-president of the Swiss Working Group for Cystic Fibrosis (SWGCF), member of the executive board of the Swiss Society of Paediatric Respiratory Medicine (SGPP) and vice-president of the Swiss Society for Sleep Research, Sleep Medicine and Chronobiology (SSSSC). Since 2020 he is the secretary of the European Respiratory Society (ERS) pediatric assembly.
Prof Moeller trained at University Children’s Hospital Zurich and Princess Margaret Hospital in Perth, WA and obtained his postdoctoral lecture qualification at the University of Zurich (UZH) 2010 and is adjunct Professor at UZH since 2018. He runs a very active specialist clinical service for the whole range of paediatric pulmonology and is leading an active research group at University Children’s Hospital Zurich. His main research focus is the non-invasive assessment of airway inflammation in children by breath analysis and he is involved as PI in clinical trials in the context of the European Cystic Fibrosis Society Clinical Trial Network (ECFS-CTN).
Prof Moeller is an associate editor for the Journal Pediatric Pulmonology. He has authored over 80 papers and book chapters on paediatric respiratory diseases.

Clare Murray is professor of paediatric respiratory medicine at the University of Manchester and an honorary consultant respiratory paediatrician at the Royal Manchester Children’s Hospital, UK. She is both an active clinician and researcher, focusing on asthma. She leads the paediatric severe asthma service for the North West of England. She has been actively involved in the Manchester Asthma and Allergy Study for over 20 years (a large birth cohort investigating risk factors for the development of asthma and allergy) and has been Chief Investigator since 2015. Amongst other research projects she is chief investigator for a large observational study (RADicA) investigating asthma diagnostic pathways and novel asthma diagnostic tests for both adults and children. She chairs the National Institute for Health Research (NIHR) Children’s Respiratory and Cystic Fibrosis Clinical Studies Group and is NIHR Children’s Research Network lead for Greater Manchester.

A/Prof. dr. Job FM van Boven is a health economics & real-world drug outcomes expert specialised in lung diseases. He is the founding director of the Medication Adherence Expertise Center Of the northern Netherlands (MAECON) and Chair of the European Network to Advance Best Practices & Technology on Medication Adherence (ENABLE) COST Action 19132. He is Principal Investigator at the Groningen Research Institute for Asthma and COPD (GRIAC) and leads the research group on Cost-effective Respiratory Drug Use at the University Medical Center Groningen.
He obtained his PharmD and PhD at the University of Groningen (The Netherlands), where his thesis focused on the cost-effectiveness of adherence enhancing interventions in patients with COPD. After his PhD research, he completed fellowships at the University of Colorado (USA), Monash University (Australia) and the Hospital Universitario Son Espases (Spain).
He is (co)author of >100 scientific publications, supervisor of 9 PhD students and received several research prices & grants (totalling>€6 million). Having interest and wide experience in both medication adherence and health economic methods, his mission is to find novel, cost-effective ways to make better use of our respiratory medications in order to maximize both patients’ and societal benefits. Amongst others, his research aims to provide evidence for optimal implementation of drug-device technologies (digital inhalers, electronic pill bottles and smart spacers) in daily clinical practice.

Graduated in Medicine from the University of Navarre (2008), he performed the training in pulmonology at the Vall d'Hebron University Hospital (2009-2103). He performed his PhD in the Autonomous University of Barcelone (UAB) (2016) regarding non-invasive airway inflammatory biomarkers in hypersensitivity pneumonitis and he is currently an Associate Professor at the UAB. He performed a research fellow for one year (2017) at the Sacré Coeur Hospital in Montreal (Canada) with a "Long Term International Fellowship" from the European Respiratory Society (ERS). He is currently an Associate Specialist Physician at the Pulmonology Service at the Vall d'Hebron University Hospital, combining clinical and research activity. His clinical activity focuses on the management of asthma (severe and occupational asthma) and interstitial lung disease (hypersensitivity pneumonitis). Regarding research activity, he combines clinical studies and animal models of asthma and hypersensitivity pneumonitis, as well as participation in clinical trials. He received the “Early Career Research Award” by the Spanish Respiratory Society in 2017 and he is currently the chair of the Emerging asthma research group” at this scientific society. He has co-authored more than 50 peer reviewed papers in international journals (http://orcid.org/0000-0003-1270-5772) and is currently involved in several competitive well funded research projects.

Chair of the ILD Unit at the Respiratory Department of University Hospital of Bellvitge and head of the Research Laboratory of Pulmonology in IDIBELL (Barcelona, Spain). Medical Doctor (1998), Pulmonologist (2003), PhD in Interstitial Lung Diseases (ILDs) (2007) and Associated Professor for ILD at the University of Barcelona (UB)(2011). Scientific director of Integral Projects of ILD at the Spanish Respiratory Society (SEPAR) and at the national consortium of respiratory research CIBERES for Lung Fibrosis. Chief of the Rare-ILD Group of Assembly 12 ILD of the ERS. Scientific advisor for the EU-IPFF. Research contributions in the ILD field, especially in lung fibrosis and rare ILDs: 120 indexed peer-reviewed articles, 32 book-chapters, direction of 6 thesis, contribution in 14 clinical trials (11 in Pulmonary Fibrosis, 3 in rare-ILDs; PAP and LAM), conducting 5 multicentre research projects, and participating in global Registries and Biobanks (EurIPF Reg., DNA consortium).

- MD, FAAAAI, Dist.Intl.FACAAI
- Directora Centro de Excelencia en Asma y Alergia, Hospital Médica Sur, Mexico City
- GINA Advocate for Mexico 2020-ongoing
- Chair 8 National Guidelines: a.o. Integrated asthma managemente (MIA 2021), Immunotherapy 2019, Consensus Atopic Derm 2018, Asthma 2017, Urticaria 2014 and ARIA México 2014
>190 pubmed indexed publications
www.dralarenas.com

Todor (Ted) A. Popov graduated medicine at the Medical University in Sofia, Bulgaria. He acquired specialties in Internal Medicine and Clinical Allergology, defended a PhD thesis on airway responsiveness and cough. He spent 2 years as visiting professor at McMaster University in Canada. He is presently professor (full) at the Clinic of Occupational Diseases by the University Hospital ‘Sv. Ivan Rilski’ in Sofia. His areas of interest include asthma diagnosis and treatment, allergic rhinitis, non-invasive methods for assessment of airway inflammation, bronchial reactivity and cough reflex measurements, biostatistics, planning and design of research studies. He is holder of over twelve national and international patents. He has a rich publishing history and is member of the editorial board and reviewer of international and Bulgarian medical journals. He is ambassador of the Global Initiative for Asthma (GINA), member and co-author of the Allergic Rhinitis and its Impact on Asthma (ARIA) group; former president of the World Asthma Association ‘INTERASMA’, former vice president of the European Academy of Allergology and Clinical Immunology (EAACI), former member of the Board of Directors of the World Allergy Organization (WAO), former president of the Union of the Bulgarian Scientific Societies. He has been part of the Respiratory Effectiveness Group since its establishment and has served as chair of the Anonymized Data Ethics and Protocol Transparency (ADEPT) Committee for two years.

Sofia, February 2022

Prof Dr Renaud LOUIS is full professor, academic head of the department of respiratory medicine at University of Liege and CHU of Liege, Belgium since 2004. He was president of the Belgian Thoracic Society from 2013 until 2014. He served as secretary of the group 5.3 allergy and Immunology of the assembly 5 “Airway diseases” at the ERS from 2002 until 2005. He currently sits in the steering committee of the SHARP (ERS research project on Severe Asthma) and is co-chair of the current ERS task force on “Diagnosis in asthma in adults”. He has focused his clinical research on asthma for 30 years developing the technique of induced sputum as a research tool to investigate mechanisms of airway inflammation but also applying it in clinical practice as an aid to asthma management. He is currently running, together with Pr Dr Schleich, a busy asthma clinic at CHU Liege with more than 200 hundreds severe asthma patients receiving regular biologics. He has become GINA advocate in 2020. He has more than 370 peer reviewed publications.in Scopus with an H Index of 50 (H index 64 in Google Scholar). He was associate editor of International Journal of Clinical Practice (section respiratory medicine) and is currently associate editor of the European Respiratory Review.

Adapted January 2022

Jean Bousquet, born in 1946, is an Honorary Professor of Pulmonary Medicine at Montpellier University, France. For 13 years, he was the Director of the Inserm (Institut de la Santé et de la Recherche Médicale) laboratory “Immunopathology of Asthma” (1994-2007). He was also the coordinator of MeDALL (Mechanisms of the Development of Allergy - Framework Programme 7 (EU) - Integrated Project 2010-2014 - FP7 success story). He has chaired GINA (Global Initiative for Asthma - 1999-2000 - National Heart, Lung and Blood Institute (NIH)) and was the ARIA (Allergic Rhinitis and its Impact on Asthma in collaboration with the World Health Organization (WHO)) founder (1999-current).
Jean Bousquet was Chairman of the WHO Global Alliance against Chronic Respiratory Diseases (GARD, 2006-2013) and is co-coordinator of the Action Plan B3 of the European Innovative Partnership on Active and Healthy Ageing (EIP on AHA, Action 5: Care Pathways, Integrated Care for Chronic Diseases). 
For many years, his research was focused on allergens and immunotherapy including pioneered work in sub-lingual immunotherapy. His focus was then directed towards asthma research and he performed studies involving bronchial biopsies which demonstrated inflammation in asthma. He proposed and demonstrated the concept of airways remodelling in asthma. He also examined the relationships between asthma and rhinitis as a co-morbidity, particularly in severe patients. He has now turned his research interest to systems biology to understand the mechanisms of allergy and chronic diseases and has proposed a new definition for IgE-mediated diseases (MeDALL).
Jean Bousquet has public health interest, in particular as the chairman of the WHO GARD. The main activity of GARD was to help implementing chronic respiratory disease programmes at national (e.g. China, Italy, Kyrgystan, Turkey) or regional (Minais Gerais, Brazil) levels and in the UN Resolution A/RES/64/265. He is currently leading the Région Languedoc-Roussillon-Midi-Pyrénées programme on chronic diseases for an active and healthy ageing (Reference Site of the European Innovative Partnership on Active and Healthy Ageing).
Jean Bousquet has always combined his research, clinical and public health interests. He performed translational research from a clinical observation in his clinic to the assessment of the disease burden (epidemiology), the understanding of the mechanisms and the implementation of the results to populations developing guidelines, national or international programmes with WHO.
Jean Bousquet has edited and authored 10 books including one allergy textbook, and over 900 peer-reviewed papers posted in Pubmed. He has over 1,150 papers listed in Research Gate. He has published 4 of the 20 most cited papers in asthma. His Hirsch (H) factor is 112. He was listed as one of the 400 most cited authors in biomedical science (Scopus 1996-2011).
He was the editor of the European Respiratory Review and of Allergy (second ranking journal in the field, 2003-2009, IF: 6.2). He is currently the editor of Clinical Translational Allergy and is or has been the associate editor of over 10 journals (IF: 3.8). 
Among the many awards, Jean Bousquet is Doctor Honoris Causa of the University 1 of Moscow, Modena and Warsaw.

President, APAAACI
Dept. of Pediatrics,
Nippon Medical School, Tokyo, Japan